Wird geladen...
The emerging role of antibody-drug conjugates in urothelial carcinoma
INTRODUCTION: In December 2019, the US Food and Drug Administration granted accelerated approval to the novel nectin-4-targeting antibody-drug conjugate, enfortumab vedotin, for the treatment of platinum-refractory and immune checkpoint blockade-refractory locally advanced or metastatic urothelial c...
Gespeichert in:
| Veröffentlicht in: | Expert Rev Anticancer Ther |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7545404/ https://ncbi.nlm.nih.gov/pubmed/32552213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737140.2020.1782201 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|